CAR T-Cell Therapy for Advanced Lymphoma: Targeted Approaches
- What: The first FDA-approved vaccine to prevent lower respiratory tract disease (LRTI) caused by respiratory syncytial virus (RSV) in adults 60 years and older.
- When: Approved May 3, 2023; data published in the New England Journal of Medicine on August 21/28, 2025.
- Why it matters: RSV causes meaningful morbidity and mortality in older adults, often leading to pneumonia and hospitalization.
RSV Vaccine Approved for Older Adults: A New shield Against Respiratory Illness
Table of Contents
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms.However, for older adults, RSV can be severe, leading to bronchiolitis and pneumonia. Before the progress of this vaccine, RSV was estimated to cause between 60,000 and 160,000 hospitalizations and 6,000 to 10,000 deaths annually among adults 65 years and older in the United States. The virus weakens the respiratory system, making individuals more vulnerable to secondary infections and exacerbating existing conditions like COPD and heart failure.
The impact of RSV extends beyond individual health. Hospitalizations strain healthcare resources, particularly during peak RSV season (typically fall and winter). A preventative vaccine, thus, offers a significant public health benefit.
The landmark clinical Trial: RSV Vaccine Efficacy and Safety
The approval of the RSV vaccine, developed by Pfizer, is based on data from a pivotal Phase 3 clinical trial involving nearly 37,000 adults aged 60 years and older. Published in the new England Journal of Medicine on August 21/28, 2025, the study demonstrated a remarkable 82.6% efficacy in preventing LRTI caused by RSV, as defined by the presence of at least two symptoms including cough, fever, and shortness of breath.
The trial also showed a 94.1% efficacy in preventing severe RSV-associated LRTI, which involved hospitalization or requiring emergency medical care. importantly, the vaccine’s efficacy was consistent across different age groups within the 60+ population and among individuals with underlying medical conditions.
Safety was carefully monitored throughout the trial. The most common adverse events were local reactions at the injection site (pain, redness, swelling) and systemic reactions such as fatigue, headache, and muscle pain. These reactions were generally mild to moderate in severity and resolved within a few days. Serious adverse events were rare and not definitively linked to the vaccine.
| Outcome | Vaccine Group Efficacy (%) | Placebo Group Rate (%) |
|---|---|---|
| RSV-Associated LRTI (≥2 symptoms) | 82.6 | 18.4 |
| Severe RSV-Associated LRTI (Hospitalization/Emergency Care) | 94.1 | 5.9 |
How the RSV Vaccine Works: A Deep Dive into the Technology
The RSV vaccine utilizes a recombinant subunit technology. This means it doesn’t contain a live virus. Instead, it contains a stabilized prefusion F protein, a key protein on the surface of the RSV virus that is crucial for the virus to enter cells. By presenting this protein to the immune system, the vaccine triggers the production of antibodies that can neutralize the virus and prevent infection.
The stabilization of the prefusion F protein is a critical innovation. RSV’s F protein naturally changes shape, and the prefusion form is the one that elicits the most protective immune response. Stabilizing this